73% of B2B buyers actively avoid suppliers that send irrelevant outreach.
That statistic should change how HealthTech founders think about lead generation.
Not because outbound is dead.
Because relevance has become part of the product.
Gartner surveyed 632 B2B buyers and found not only that 73% actively avoid suppliers sending irrelevant outreach, but that buyers increasingly prefer seller involvement when they need contextual intelligence, such as determining whether a solution actually fits their organisation.
That distinction matters.
A hospital executive does not need another vendor explaining what AI is.
A biotech investor does not need another generic pitch telling them the market is large.
A commercial leader at a HealthTech company does not necessarily need another spreadsheet containing 200 names.
They need help answering harder questions:
Which opportunity deserves attention?
Why does it matter now?
Who actually influences the decision?
What commercial argument will make the conversation relevant?
What should happen next?
That is why I increasingly think the missing layer between market intelligence and revenue is not lead generation.
It is commercial opportunity intelligence.
Commercial Opportunity Prioritization Diagnostic
Estimate whether your pipeline, priority account, event plan or stalled opportunity is commercially focused enough to deserve the next 30 days of founder, executive and investor attention.
1. Commercial Context
Use directional estimates. The goal is to reveal whether your team is spending time on opportunities with enough fit, timing and commercial logic.
2. Score Your Commercial Opportunity Stack
Score what is actually proven today. Low scores reveal where a promising account, deal or market can still fail to convert into commercial momentum.
3. Founder / Investor Risk Flags
These are the weaknesses most likely to make a large pipeline look better than it really is.
- Decision-maker access is currently weak.
- Why-now evidence needs sharpening.
- The stakeholder map may be incomplete.
4. 30-Day Commercial Action Plan
A practical sequence to turn the weakest part of the opportunity stack into a clearer next move.
- Prioritize the top five opportunities by fit, urgency, access and value.
- Map the missing decision-maker and blocker for each priority account.
- Build a specific why-now signal and next-step ask before more outreach.
Need help turning the diagnosis into a commercial action plan?
This diagnostic identifies where the opportunity stack is weak. The linked GrowthVybz sprint goes deeper into buyer logic, value evidence, stakeholder mapping and the commercial actions needed to move a live opportunity.
HealthTech has an abundance problem
Look at the current HealthTech and life-sciences event ecosystem.
HETT says its 2026 event will bring together 3,000+ public-sector healthcare professionals, 150 innovative suppliers and 250+ speakers, with 81% of attendees influencing or signing off purchasing and investment decisions.
BioTechX USA advertises 1,500+ attendees, 100+ exhibitors, 50+ biotech startups and 200+ speakers across data, AI, diagnostics, precision medicine and healthcare.
LSX Congress USA lists 1,000+ senior attendees and 300+ investors, with a programme explicitly covering partnering, market opportunities, market access and commercialization.
BIOSPAIN expects more than 5,000 one-to-one meetings during its 2026 edition. Its partnering platform lets delegates filter by company, geography, therapeutic area, company type and asset stage before scheduling conversations.
That sounds like enormous opportunity.
It is.
But it creates another problem:
More access creates more decisions.
If there are 1,000 people you could talk to, the value does not come from knowing 1,000 names.
It comes from correctly identifying the 5, 10 or 20 relationships that are disproportionately relevant to what your company needs right now.
The ecosystem is not one market
One reason generic prospect lists perform poorly is that HealthTech and biotech ecosystems contain fundamentally different types of organisations.
Here are some of the companies I have been tracking across current event, partnering and commercial ecosystems:
| Commercial category | Examples | What founders should be looking for |
|---|---|---|
| Digital Health & Healthcare Platforms | Newton’s Tree, Recare, Savana, Dedalus, LOGEX | Hospital access, implementation partnerships, interoperability, workflow ROI, data infrastructure |
| Biotech Innovators | 42Genetics, 9Bio Therapeutics, Aether Therapeutics, AllerGene AI Therapeutics, Alveus Therapeutics | Pharma partnering, capital, licensing, clinical development, strategic collaboration |
| Diagnostics, Data & AI | Robust Diagnostics, AI VIVO, BioPredX, Eterna Diagnostics, Health in Code | Clinical validation, data access, provider adoption, strategic distribution, payer/provider evidence |
| Pharma & Strategic Corporates | AbbVie, Sanofi, Almirall, Amgen, Bristol Myers Squibb | BD&L, partnerships, licensing, therapeutic alignment, strategic acquisition potential |
| Investors & Capital | Agent Capital, Aditum Bio, Asabys Partners, Ysios Capital Partners, Columbus Venture Partners | Investment thesis fit, stage, geography, therapeutic focus, commercial proof |
There is current public evidence behind much of this ecosystem. LSX's 2026 attendee directory, for example, includes 42Genetics, 9Bio Therapeutics, Aether Therapeutics, AllerGene AI Therapeutics, Alveus Therapeutics, Robust Diagnostics, AI VIVO, AbbVie, Sanofi, Bristol Myers Squibb, Agent Capital and Aditum Bio.
BIOSPAIN's current 2026 participant directory includes companies such as BioPredX, Almirall, Amgen/BMS and Ysios Capital Partners, while Asabys Partners appears in its current investor list.
The DNV digital-health ecosystem includes Recare and Newton's Tree, while public event announcements confirm Savana CEO Miriam Rodríguez González and LOGEX CEO Christoph Knaack for the September 2026 Digital Health Summit; Dedalus chair Andrea Fiumicelli has also been publicly identified among the speakers.
A qualification note matters here: Health in Code and Columbus Venture Partners appear in BIOSPAIN's historical/previous-edition records rather than the current 2026 section I could verify, and I did not find current-event evidence for Eterna Diagnostics. Eterna itself is active in 2026, with a genetics, biomarker, proteomics and wearable-data platform, but I would treat it as an ecosystem example rather than claim confirmed attendance at one of these events.
That distinction is exactly what good commercial intelligence should do:
separate what looks interesting from what is actually evidenced.
Framework 1: The Event Opportunity Priority Matrix
My starting framework is:
Buyer Fit × Urgency × Access × Revenue Potential
Instead of ranking a prospect because the logo is impressive, score it across four dimensions.
Buyer Fit
Does the organisation actually have the problem your company solves?
A prestigious hospital with no relevant use case can be less commercially valuable than a smaller system actively trying to solve exactly your problem.
Urgency
Is there evidence suggesting this organisation may need to act?
Examples include:
funding, expansion, new leadership, hiring, new clinical programmes, procurement activity, digital-transformation initiatives, partnerships, product launches or entry into a new geography.
Access
Can you realistically reach someone capable of moving the opportunity?
A high-fit company with no credible route to the buying group can remain theoretical.
Revenue Potential
If the conversation progresses, is the commercial outcome meaningful enough to justify executive attention?
This does not mean chasing only the biggest possible contract.
It means matching potential value against probability, sales effort and strategic importance.
Framework 2: The 100 → 20 → 10 → 5 system
This is the framework behind the visual I recently developed:
100 potential accounts → 20 qualified accounts → 10 relevant people → 5 priority conversations
Each stage answers a different question.
100 potential accounts
This is discovery.
Conference directories, LinkedIn, CRM data, investor lists, market maps, partner directories and ecosystem research can all feed this stage.
Technology makes this relatively easy.
And that is exactly why this stage is becoming less valuable on its own.
20 qualified accounts
Now apply commercial filters.
Remove companies with:
weak product fit, wrong geography, wrong stage, no visible need, limited strategic relevance or no plausible route to a conversation.
10 relevant people
An account is not a buyer.
A hospital may involve:
clinical leadership, procurement, finance, IT, innovation, operations and executive management.
A biotech partnership could involve:
business development, licensing, R&D, corporate development or investment teams.
Different people can have completely different reasons for saying yes or no.
5 priority conversations
Finally ask:
If our CEO or CCO could have only five serious conversations, which ones would we choose?
That constraint forces better decisions.
Framework 3: Build a Why-Now Signal Stack
This is one of the most important differences between contact research and commercial intelligence.
I do not just want to know:
“Who is the VP of Business Development?”
I want to know:
“Why might talking to this VP this month be more relevant than talking to them six months ago?”
A simple signal stack can include:
Market signal → expansion, new geography, strategic shift
Company signal → funding, acquisition, partnership, leadership hire
Buyer signal → procurement programme, innovation initiative, capacity problem
Product signal → launch, regulatory milestone, clinical evidence
Timing signal → event participation, budgeting cycle, strategic announcement
One weak signal is interesting.
Several aligned signals can create a commercial hypothesis.
That still does not mean the organisation will buy.
But it gives the conversation a reason to exist.
Framework 4: Map the buying group, not just the contact
HealthTech selling is rarely a one-person decision.
A conversation can stall even when the person you met genuinely likes the product.
Why?
Because approval may depend on completely different stakeholders.
For a hospital opportunity, I might ask:
Who feels the problem?
Who owns the budget?
Who evaluates clinical value?
Who evaluates technical risk?
Who manages procurement?
Who could veto implementation?
Who benefits economically if the product works?
Now the commercial problem changes.
Instead of:
“How do I convince my contact?”
it becomes:
“How do I help my contact build an internal case?”
That is a much more useful question.
Framework 5: Translate features into buyer economics
Commercial relevance ultimately needs to survive internal scrutiny.
A founder may describe the product as:
AI-powered
interoperable
automated
predictive
patient-centric
Those may all be true.
But a buyer may need to justify:
hours saved
capacity released
avoidable cost reduced
revenue captured
length of stay changed
administrative burden reduced
diagnostic workflow improved
clinical risk reduced
staff productivity increased
The strongest ROI case will differ by product.
That is why I like building a mini value case around three layers:
Operational value
What changes in the workflow?
Economic value
What measurable resource, cost, revenue or capacity effect could matter?
Evidence requirement
What proof does the buyer need before believing the economic argument?
The final question is particularly important.
A spreadsheet showing attractive ROI does not automatically create a credible business case.
Framework 6: Give every opportunity a next-step objective
A surprisingly common commercial failure is finishing a meeting with:
“Great conversation. Let's stay in touch.”
That is networking.
Not pipeline progression.
Before an important conversation, define the intended next step.
For example:
Clinical evaluation
→ technical review
→ economic validation
→ pilot discussion
→ procurement introduction
→ partnership call
→ investor diligence
→ senior stakeholder introduction
→ follow-up evidence request
A useful conversation should ideally reveal what has to happen next, even when the answer is:
“This isn't a priority right now.”
Deprioritizing the wrong opportunity is also valuable.
It returns executive time to something with a higher probability of moving.
What each part of the ecosystem requires
Digital Health: translate implementation into measurable value
For companies such as Newton's Tree, Recare, Savana, Dedalus and LOGEX, commercial intelligence has to go beyond “find hospitals.”
DNV's own 2026 Summit agenda highlights real-world implementation, measurable impact, scaling, ROI and why deployments succeed or fail.
That should tell founders something.
The commercial question is increasingly:
Where does this product create enough organisational value to survive implementation friction?
The key intelligence layer therefore includes:
provider fit, workflow, interoperability dependency, evidence, budget owner, implementation stakeholder and value metric.
Biotech: distinguish capital conversations from strategic ones
For companies such as 42Genetics, 9Bio Therapeutics, Aether Therapeutics, AllerGene AI Therapeutics and Alveus Therapeutics, the right conversation may not be a customer conversation at all.
It might be:
an investor, licensing partner, pharmaceutical company, co-development partner or strategic acquirer.
LSX itself separates investment, partnering and commercialization into meaningful parts of the ecosystem.
So I would not score every contact using the same model.
An investor needs investment-thesis fit.
A pharma partner needs asset/strategic fit.
A commercial partner needs market-access fit.
Same conference.
Different objective.
Diagnostics & AI: evidence becomes the bridge
For Robust Diagnostics, AI VIVO, BioPredX, Eterna Diagnostics and Health in Code, the commercially important questions tend to become sharper:
What workflow does this change?
Who trusts the output?
What validation exists?
Who pays?
What system needs to integrate it?
What evidence makes adoption defensible?
The mistake is jumping directly from technical capability to sales outreach.
The missing layer is usually:
technical value → clinical relevance → operational impact → economic case → buying stakeholder
Pharma: ask what strategic problem you solve
Companies such as AbbVie, Sanofi, Almirall, Amgen and Bristol Myers Squibb sit on the other side of an enormous volume of partnership approaches.
Simply being innovative does not make a startup strategically relevant.
A founder needs a credible hypothesis about:
therapeutic alignment
portfolio relevance
technology fit
development stage
geographic relevance
strategic timing
what the larger company gains
The goal is not:
“We want a partnership with Pharma X.”
It is:
“Here is why this particular capability may matter to this particular company now.”
That is substantially harder.
And therefore substantially more valuable.
Investors: fundraising lists are not investor strategy
The same applies to Agent Capital, Aditum Bio, Asabys Partners, Ysios Capital Partners and Columbus Venture Partners.
LSX already lists hundreds of investors. BIOSPAIN already provides sophisticated partnering infrastructure.
So the information advantage is not:
“Here are investors.”
The advantage is:
Which investor fits our stage?
Which fits our category?
Who has relevant portfolio exposure?
Who invests in our geography?
What evidence will they challenge?
What commercial weakness will appear in diligence?
Why is this a logical conversation now?
For investors evaluating HealthTech companies, the same framework works in reverse.
They can ask:
Is this startup's pipeline genuine commercial traction, or just a large list of organisations?
The Commercial Opportunity Stack
This is the system I would want in front of me before allocating serious founder or executive time:
1. Market universe
Who could matter?
↓
2. Opportunity qualification
Who actually fits?
↓
3. Why-now intelligence
Who has an observable reason to engage?
↓
4. Stakeholder map
Who can move or block the decision?
↓
5. Value case
Why would the organisation care economically or strategically?
↓
6. Conversation angle
What makes the outreach relevant?
↓
7. Next-step objective
What specifically should happen after the conversation?
That is the bridge between:
market intelligence → commercial intelligence → action
A useful opportunity dashboard
For every serious account, I would want to see something like this:
| Variable | Question |
|---|---|
| Buyer fit | Does this organisation genuinely fit the ICP/use case? |
| Urgency | What evidence suggests action could matter now? |
| Commercial value | What could progressing this relationship be worth strategically/economically? |
| Access | Can we reach the relevant stakeholder? |
| Decision-maker | Who influences, owns or blocks the decision? |
| Why now | What recent trigger makes outreach relevant? |
| Buyer problem | What problem are we actually attaching ourselves to? |
| Value case | How could the buyer justify action internally? |
| Objection | What is most likely to stop progression? |
| Next move | What specific outcome are we asking for? |
The score itself is less important than the discipline.
The framework forces the team to justify why an opportunity belongs at the top of the list.
The ROI question founders should ask
The cost of poor prioritization is not simply:
“We didn't close this prospect.”
It includes founder time.
BD time.
Executive meetings.
Research.
Travel.
Conference spending.
Follow-up.
Technical resources.
Pilot work.
And the opportunity cost of not pursuing something stronger.
This is why I use an ROI/decision-risk calculator alongside the framework.
Not to claim:
“Spend €595 and make €50,000.”
That would be meaningless.
Instead, model your own assumptions:
monthly commercial team cost × months of delay
plus
potential opportunity value × probability exposure
Then compare that with the cost of getting the commercial decision clearer.
The purpose is not to forecast a sale.
It is to make decision risk visible.
The missing link I increasingly see
Most founders do not suffer from a complete lack of information.
They have:
LinkedIn.
Sales Navigator.
CRM data.
conference apps.
investor lists.
market reports.
advisors.
AI research tools.
The bottleneck is often turning all that information into:
“What should we do next?”
That is the part I am increasingly building GrowthVybz around.
I don't want to give a HealthTech founder another 100 names if the real problem is that they already have 50 opportunities and do not know which five deserve the next month.
I don't want to produce another market map if the important question is why an existing hospital conversation is not moving.
And I don't want to call something “personalized outreach” simply because the first sentence contains the recipient's company name.
The commercial intelligence has to come first.
HealthTech Commercial Opportunity Sprint™
That is why I created the HealthTech Commercial Opportunity Sprint™.
It starts with one live commercial problem, such as:
a crowded pipeline, a priority hospital account, a stalled deal, an important event or a market-entry decision.
Over three business days, I turn that problem into:
5 priority opportunities
5–10 relevant decision-makers
why-now commercial signals
one deep-dive account intelligence brief
a mini ROI/value case
five tailored outreach messages
opportunity prioritization
a commercial next-step plan
30-minute strategy handover
The objective is not to promise meetings or revenue.
It is to reduce the gap between information and a defensible commercial decision.
See the HealthTech Commercial Opportunity Sprint™
The question I would leave every founder with
Before adding another 100 leads, ask:
If my team could pursue only five opportunities for the next 30 days, which five would I choose, and could I defend why?
If the answer is obvious, good.
Your commercial strategy is probably focused.
If the answer requires opening five spreadsheets, searching LinkedIn, checking old meeting notes, asking the BD team, rereading a conference directory and guessing which opportunities are alive...
you may not have a lead problem.
You may have a commercial prioritization problem.
And fixing that can be considerably more valuable than finding another list of names.
